Aldosterone and aldosterone antagonism in systemic hypertension

Current Hypertension Reports

Volumn 6, Issue 3, 2004, Pages 195-200

  Frishman, William H ^a   Stier Jr , Charles T ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; LOSARTAN; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; ALDOSTERONE RECEPTOR;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BLOOD VESSEL; BRAIN REGION; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG APPROVAL; DRUG EFFICACY; DRUG METABOLISM; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG USE; ELECTROLYTE BALANCE; FATALITY; FLUID BALANCE; GYNECOMASTIA; HEART; HEART ARRHYTHMIA; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; MASTALGIA; MENSTRUAL IRREGULARITY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM; BLOOD PRESSURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; PHYSIOLOGY;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION; RECEPTORS, ALDOSTERONE;

EID: 4644296281     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-004-0069-6     Document Type: Review

References (52)

1. Simpson SA, Tait JF: Secretion of a salt-retaining hormone by the mammalian adrenal cortex. Lancet 1952, 263: 226-228.
2. Christ M, Meyer C, Sippel K, Wehling M: Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C-alpha. Biochem Biophys Res Commun 1995, 213: 123-129.
3. Schneider M, Ulsenheimer A, Christ M, Wehling M: Nongenomic effects of aldosterone on intracellular calcium in porcine endothelial cells. Am J Physiol 1997, 272: E616-E620.
4. Stier CT Jr, Chander PN, Rocha R, et al.: Non-epithelial effects of aldosterone. Curr Opin Endocrinol Diab 1998, 5: 211-216.
5. Stier CT Jr, Koenig S, Lee DY, et al.: Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra). Heart Dis 2003, 5: 102-118.
6. Farquharson CAJ, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101: 594-597.
7. Rajagopalan S, Pitt B: Aldosterone antagonists in the treatment of hypertension and target organ damage. Curr Hypertens Rep 2001, 3: 240-248.
8. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD: Aldosterone regulates vascular reactivity. Short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 2003, 108: 2400-2406.
9. Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992, 120: 893-901.
10. Rossi GP, DiBello V, Ganzaroli C, et al.: Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002, 40: 23-27.
11. Stier CT Jr, Chander PN, Gutstein WH, et al.: Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens 1991, 4: 680-687.
12. Arora RB, Somani P: Ectopic arrhythmia provoking action of aldosterone. Life Sci 1962, 5: 215-218.
13. Vaughan DE, Lamas GA, Pfeffer MA: Role of left ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction. Am J Cardiol 1990, 66: 529-532.
14. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995, 95: 995-1001.
15. Zannad F: Aldosterone and heart failure. Eur Heart J 1995, 16(Suppl N): 98-102.
16. Struthers AD: Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 1995, 16 (Suppl N): 103-106.
17. RALES Investigators: Effectiveness of spironolactone added to an angiotensin converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996, 78: 902-907.
18. Struthers AD: Aldosterone: cardiovascular assault. Am Heart J 2002, 144: S2-7.
19. Funder JW: New biology of aldosterone and experimental studies on the selective aldosterone blocker eplerenone. Am Heart J 2002, 144: S8-S11.
20. Rossi GP, Sacchetto A, Visentin P, et al.: Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996, 27: 1039-1045.
21. Suzuki G, Morita H, Mishima T, et al.: Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002, 106: 2967-2972.
22. Yee KM, Struthers AD: Aldosterone blunts the baroreflex response in man. Clin Sci 1998, 95: 687-692.
23. McKelvie RS, Yusaf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of the strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999, 100: 1056-1064.
24. Funder JW, Pearce PT, Smith R, Smith AI: Mineralocorticoid action target tissue specificity is enzyme, not receptor, mediated. Science 1988, 242: 583-585.
25. Pearce P, Funder JW: High affinity aldosterone binding sites (type 1 receptors) in rat heart. Clin Exp Pharmacol Physiol 1987, 14: 859-866.
26. Lombes AM, Alfaidy N, Eugene E, et al.: Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995, 92: 175-182.
27. Schneider M, Ulsenheimer A, Christ M, Wehling M: Nongenomic effects of aldosterone on intracellular calcium in porcine endothelial cells. Am J Physiol 1997, 272 (4 Part 1): E616-620.
28. Gomez-Sanchez EP, Fort CM, Gomez-Sanchez CE: Intracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension. Am J Physiol 1990, 258 (3 Part 1): E482-E484.
29. Young M, Head G, Funder J: Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995, 269: E657-E662.
30. Berecek KH, Stocker M, Gross F: Changes in renal vascular reactivity at various stages of deoxycorticosterone hypertension in rats. Circ Res 1980, 46: 619-624.
31. Weber MA, Purdy RE: Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle. Life Sci 1982, 30: 2009-2017.
32. Wang M, McClaim JM, Zucker IH: Aldosterone reduces baroreceptor discharge in the dog. Hypertens 1992, 19: 270-277.
33. Benetos A, Lacolley P, Safar ME: Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997, 17: 1152-1156.
34. Rocha R, Stier CE Jr: Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001, 12: 308-314.
35. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (The JNC 7 report). The National High Blood Pressure Education Program Coordinating Committee JAMA 2003, 289: 2560-2572.
36. Gehr TWB, Sica DA, Frishman WH: Diuretic therapy in cardiovascular disease. In Cardiovascular Pharmacotherapeutics, edn 2. Edited by Frishman WH, Sonnenblick EH, Sica DA. New York: McGraw Hill; 2003:157-176.
37. Burgess E, Niegowska J, Tan W, et al.: Antihypertensive effects of eplerenone and enalapril in patients with essential hypertension [abstract]. Am J Hypertens 2002, 15(Suppl): 23A.
38. Weinberger MH, MacDonald T, Conlin PR, et al.: Comparison of eplerenone and losartan in patients with low-renin hypertension. The Eplerenone 019 Investigators [abstract]. Am J Hypertens 2002, 15(4 Part 2): 24A.
39. White WB, Lewin AJ, Nestel R, et al.: Comparison of selective aldosterone blockade versus calcium antagonism on blood pressure, vascular compliance, and microalbuminuria in systolic hypertension in older people. The Eplerenone 022 Investigators [abstract]. Am J Hypertens 2002, 15(Suppl): 23A.
40. Weinberger MH, Roniker B, Krause SL, Weiss RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15: 709-716.
41. Weber MA: Clinical implications of aldosterone blockade. Am Heart J 2002, 144: S12-S18.
42. Weir MR, Saunders E: Pharmacologic management of systemic hypertension in blacks. Am J Cardiol 1988, 61: 46H-52H.
43. Weir MR: Impact of age, race, and obesity on hypertensive mechanisms and therapy. Am J Med 1991, 90(Suppl 5A): 3S-14S.
44. Flack JM, Oparil S, Pratt JH, et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients. J Am Coll Cardiol 2003, 41: 1148-1155.
45. Gibbs CR, Beevers DG, Lip GY. The management of hypertensive disease in black patients. QJM 1999, 92: 187-192.
46. Epstein M, Buckalew V Jr, Martinez F, et al.: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination theapy in diabetic hypertensives with microalbuminuria. The Eplerenone 021 Investigators [abstract]. Am J Hypertens 2002, 15: 24A.
47. Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41: 64-68.
48. Pitt B, Reichek N, Metscher B, et al.: Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy in patients with left ventricular hypertrophy The Eplerenone 017 Investigators [abstract]. Am J Hypertens 2002, 15: 23A.
49. Rajagopalan S, Duquaine D, King S, et al.: Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002, 105: 2212-2216.
50. Susic D, Varagic J, Ahn I, et al.: Eplerenone improves coronary hemodynamics and reduces cardiac fibrosis in aging spontaneously hypertensive rats [abstract]. J Am Coll Cardiol 2004, 43(SupplA): 482a.
51. de Paula RB, da Silva AA, Hall JE: Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004, 43: 41-47.
52. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. N Engl J Med 2003, 348: 1309-1321.